Ciprofloxacin In Urine Research Articles

Degradation of the antibiotic ciprofloxacin in urine by electrochemical oxidation with a DSA anode

Ciprofloxacin (CIP) is a commonly prescribed fluoroquinolone antibiotic that, even after uptake, remains unmetabolized to a significant extent—over 70%. Unmetabolized CIP is excreted through both urine and feces. This persistent compound manages to evade removal in municipal wastewater facilities, leading to its substantial accumulation in aquatic environments. This accumulation raises concerns about potential risks to the health of various living organisms. Herein, we present a study on the remediation of CIP in synthetic urine by electrochemical oxidation in an undivided cell with a DSA (Ti/IrO2) anode and a stainless-steel cathode. Physisorbed hydroxyl radical formed at the anode surface from water discharge and free chlorine generated from Cl− oxidation were the main oxidizing agents. The effect of pH and current density (j) on CIP degradation was examined, and its total removal was easily achieved at pH ≥ 7.0 and j ≥ 60 mA cm−2 due to the action of free chlorine. The CIP decay always followed a pseudo-first-order kinetics. The components of the synthetic urine were also oxidized. The main nitrogenated species released was NH3. A very small concentration of free chlorine was quantified at the end of the treatment, thus demonstrating the good performance of electrochemical oxidation and its effectiveness to destroy all the organic pollutants. The present study demonstrates the simultaneous oxidation of the organic components of urine during CIP degradation, thus showing a unique perspective for its electrochemical oxidation that enhances the environmental remediation strategies.

Detection of Ciprofloxacin in Urine through Sensitized Lanthanide Luminescence.

Ciprofloxacin, a fluoroquinolone antibiotic, is widely used for the treatment of bacterial infection in humans due to its broad antibacterial spectrum. An excessive use or overdose of ciprofloxacin on the other hand can cause several adverse effects not only to humans but also to microorganisms. Unabsorbed ciprofloxacin in the body is mostly excreted through urine and finally goes to the environment, providing a drug resistance pressure on bacteria. Hence a simple and efficient detection method of ciprofloxacin is necessary, which, for example, can be used to analyze ciprofloxacin content in urine. Although ciprofloxacin itself shows inherent fluorescence, direct fluorescent detection of ciprofloxacin in raw urine sample is difficult due to autofluorescence of urine by other components. Herein we report that a Tb(III) complex of DO3A (1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid) can be efficiently sensitized by ciprofloxacin to emit luminescence separately from the urine autofluorescence wavelength region. Tb-DO3A shows excellent sensitivity with a detection limit of three parts per billion in aqueous buffer solution. Further, Tb-DO3A is used to detect ciprofloxacin with high sensitivity and selectivity in a raw urine sample without any purification or separation procedures in the concentrations ranging from 1 µg·mL−1 to 50 µg·mL−1. The direct measurement of ciprofloxacin excreted in urine may be used to control overdose of the drug.

Rapid determination of ciprofloxacin in urine by matrix isopotential synchronous spectrometry

A simple, rapid and sensitive synchronous fluorescence method is proposed for the determination of ciprofloxacin in urine. The combination of matrix isopotential synchronous fluorescence (MISF) and first derivative techniques provides good analytical results. MISF spectra are obtained by calculating an isopotential trajectory in the three-dimensional fluorescence spectrum of urine solutions. This trajectory is chosen so that it passes by the fluorescence maxima of ciprofloxacin (λex = 277 nm and λem = 444 nm). Analyses were carried out in an ethanol–water medium (10% v/v), with an apparent pH of 4.8 kept constant by using a sodium acetate/acetic acid buffer solution. The linear range of concentration was between 40 and 400 ng mL−1. Exhaustive statistical analyses were made of all calibration graphs. The detection limit according to the error propagation theory was 5.6 ng mL−1 and the detection limit proposed by Clayton was 13.5 ng mL−1. The repeatability of the method was determined for two series of ten solutions containing 40 and 180 ng mL−1 of ciprofloxacin in urine, respectively. By applying the IUPAC definition, the relative errors were 9.5% and 2.0%, while, based on error propagation, the relative errors were 6.3% and 1.2%, respectively.

Identification and quantification of ciprofloxacin in urine through excitation-emission fluorescence and three-way PARAFAC calibration

Due to the second-order advantage, calibration models based on parallel factor analysis (PARAFAC) decomposition of three-way data are becoming important in routine analysis. This work studies the possibility of fitting PARAFAC models with excitation-emission fluorescence data for the determination of ciprofloxacin in human urine. The finally chosen PARAFAC decomposition is built with calibration samples spiked with ciprofloxacin, and with other series of urine samples that were also spiked. One of the series of samples has also another drug because the patient was taking mesalazine. The mesalazine is a fluorescent substance that interferes with the ciprofloxacin. Finally, the procedure is applied to samples of a patient who was being treated with ciprofloxacin. The trueness has been established by the regression “predicted concentration versus added concentration”. The recovery factor is 88.3% for ciprofloxacin in urine, and the mean of the absolute value of the relative errors is 4.2% for 46 test samples. The multivariate sensitivity of the fit calibration model is evaluated by a regression between the loadings of PARAFAC linked to ciprofloxacin versus the true concentration in spiked samples. The multivariate capability of discrimination is near 8 μg L −1 when the probabilities of false non-compliance and false compliance are fixed at 5%.

Ciprofloxacin Decreased Polyoma BK Virus Load in Patients Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation

Polyoma BK virus (BKV) is associated with hemorrhagic cystitis during hematopoietic stem cell transplantation (HSCT). The objective of this study was to test whether standard-dose ciprofloxacin might suppress reactivation of BKV infection during HSCT. Sixty-eight patients received ciprofloxacin or a cephalosporin as antibiotic prophylaxis after undergoing allogeneic HSCT. Urine samples were collected weekly from day 7 before HSCT to day 50 after HSCT. Laboratory investigations included quantification of BKV load and urinary ciprofloxacin levels and in vitro drug sensitivity of BKV. Twenty-two patients received ciprofloxacin, 21 received cephalosporins, 12 received concomitant corticosteroids and antibiotics (9 received ciprofloxacin, and 3 received cephalosporins), and 13 received interrupted ciprofloxacin therapy. Ciprofloxacin recipients developed a significantly lower peak BKV load, compared with cephalosporin recipients (median, 3x10(5) copies/mL vs. 2.6x10(9) copies/mL; P=.021), irrespective of concomitant receipt of corticosteroid therapy. Fewer ciprofloxacin recipients than cephalosporin recipients (P=.013) developed BKV viruria with a > or =3-log increase in BKV load during HSCT, which was associated with significantly more cases of hemorrhagic cystitis (8 of 29 patients with a peak increase of > or =3 log vs. 0 of 39 patients without a peak increase of this level; P<.001). Ciprofloxacin recipients excreted ciprofloxacin in urine at a mean 24-h rate of 71.7 microg/mL (range, 23.0-152.9 microg/mL), which was comparable with the in vitro inhibitory concentration of 125-250 microg/mL of ciprofloxacin found for 3 of 7 BKV isolates. Ciprofloxacin decreased urinary BKV reactivation after HSCT.

High concentration of ciprofloxacin in urine invalidates EMIT results.

High concentration of ciprofloxacin in urine invalidates EMIT results.

Comparison of adsorptive stripping voltammetry at mercury and carbon paste electrodes for the determination of ciprofloxacin in urine

AbstractWe compared hanging mercury drop electrodes (HMDEs) and carbon paste electrodes (CPEs) for the determination by adsorptive stripping voltammetry (AdSV) of the antibiotic ciprofloxacin in urine. The antibiotic compound could be preconcentrated at both electrode surfaces, with carbon paste electrode yielding a better performance. These electrodes could be used to determine between 6 × 10−7 and 4 × 10−6 M ciprofloxacin in urine. A cleanup procedure (with 81% recovery), utilizing a C18 Sep Pak cartridge, was required to separate ciprofloxacin from the biological matrix prior to adsorptive stripping analysis. The method was applied to the determination of ciprofloxacin in spiked urine samples with a relative standard deviation of 4.1%.

Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function

The pharmacokinetics of ciprofloxacin following single oral doses of 500 and 750 mg in 32 patients with various degrees of renal function impairment were investigated in an open, randomized crossover fashion. Ciprofloxacin was administered after overnight fasting; the washout time between the two doses was 1 week. Serum and urine samples were collected serially between 0 and 24 h and subjected to bioassay and high-performance liquid chromatography. Pharmacokinetic parameters were analyzed, assuming an open two-compartment model with first-order input and elimination. A distinct difference was observed in pharmacokinetic parameters between patients with impaired renal function (creatinine clearance, less than 50 ml/min per 1.73 m2) and those with normal renal function (creatinine clearance, greater than or equal to 50 ml/min per 1.73 m2). For the former group, the area under the curve of serum concentration versus time was doubled, the renal clearance of ciprofloxacin was cut to one-fourth, the total and nonrenal ciprofloxacin clearance was reduced by 50%, and the elimination half-life was prolonged by a factor of approximately 1.7. The correlation between renal drug clearance and creatinine clearance was highly significant (r = 0.890; P less than 0.001). On the basis of these findings, it appears that a 50% dose reduction of ciprofloxacin in patients with impaired renal function (creatinine clearance, less than 50 ml/min per 1.73 m2) may be indicated to achieve concentrations in serum similar to those observed in normal individuals. As the concentration of ciprofloxacin in urine after 24 h remained above the MIC for most urinary pathogens, this drug appears to be of potential benefit for the treatment of urinary tract infections in patients with impaired renal function.